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A Superior Route to
Deliver Therapeutics to the Heart?*
Frank J. Giordano, MD
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As the genomics and proteomics revolutions progress and
the molecular biology of various cardiovascular pathologies
is better understood, an increasing number of potential
molecular therapies are being proposed. The ultimate suc-
cess of any of these therapies depends upon many factors,
including the biological activity of the therapeutic agents
and the ability to deliver them to the proper cellular targets.
Some of these agents may be effective when delivered
systemically, whereas others may be safer and/or more
effective when delivered locally. The use of drug-eluting
stents to deliver anti-restenosis agents directly to targeted
coronary segments is an excellent example of an effective
“marriage” of a bioactive agent and an optimized local
delivery strategy (1). In this issue of the Journal, von
Degenfeld et al. (2) describe the use of an alternative
delivery technique, retrograde coronary venous perfusion
(RCVP), to deliver the angiogenic protein fibroblast growth
factor-2 (FGF-2) to ischemic porcine hearts.
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Several strategies have been used to deliver angiogenic
factors to the heart (3–10). The broadest division of these
strategies is between the delivery of angiogenic genes or of
intact angiogenic proteins (11,12). The intuitive argument
for angiogenic gene therapy is based partially on the fact
that most angiogenic proteins have a very short in vivo
half-life. The gene therapy argument states that the only
way to ensure exposure of the heart to sufficient angiogenic
protein for a sufficient duration to produce therapeutic
angiogenesis is by local production of the protein after gene
delivery. The failure of two placebo-controlled angiogenic
protein delivery clinical trials to meet pre-determined effi-
cacy end points has supported this position (13,14). As
controlled clinical data accumulates from angiogenic gene
therapy trials, however, it appears that even sustained
exposure to a single angiogenic gene product may not be
enough to replicate the remarkable therapeutic benefits
documented in preclinical animal studies, despite some
evidence of effect (15,16). The biology of angiogenesis is
quite complex, and optimal therapeutic stimulation of
angiogenesis may require multiple factors or splice variants
(17). Thus, both the questions of optimal delivery strategy
and optimal therapeutic agent(s) remain open.
Anterograde intracoronary (IC) delivery of FGF-2 has
been previously shown to yield relatively poor myocardial
delivery and may explain in part why an IC FGF-2 clinical
trial was disappointing (13,18). Anterograde IC delivery of
the FGF-5–encoding adenovirus was, however, shown to
effectively induce therapeutic angiogenesis in a porcine
ameroid ischemia model, and this approach is now in phase
III clinical testing (4,15). Despite the preclinical success of
this IC adenovirus delivery approach, the degree of gene
delivery to the myocardium achieved in this manner is quite
variable and most often quite low. The endothelium of the
coronary microvasculature is continuous and presents a
formidable barrier to the passage of macromolecules, such as
viral vectors, to the myocardium. This barrier function can
be partially overcome with mechanical maneuvers that
increase anterograde perfusion pressure and by pharmaco-
logic methods that increase vascular permeability (19,20).
To date, none of these methods has been readily adaptable
to percutaneous delivery of therapeutic agents in the cardiac
catheterization lab. The retrograde perfusion technique used
by von Degenfeld et al. (2) may be a cath lab-friendly
technique that overcomes some of the limitations of intra-
coronary delivery.
In their study, von Degenfeld et al. (2) used covered
stents in a novel percutaneous approach to induce ischemia
in the left anterior descending artery territory of pigs. They
then tested the ability of RCVP of FGF-2 protein to induce
angiogenesis and ameliorate myocardial ischemia in these
pigs. Although complete resolution of perfusion and func-
tion defects was not achieved, retrograde infusion of FGF-2
did improve both flow and function in these animals,
induced increased capillary density, and was more effective
than anterograde infusion of FGF-2. Using radiolabeled
FGF-2 protein, the authors demonstrated an over twofold
increase in the amount of FGF-2 delivered to the heart with
retrograde infusion versus anterograde. This may explain in
part why this delivery route achieved more effective resto-
ration of flow and function. Another possible explanation
put forth by the investigators is that retrograde infusion
results in a different distribution of FGF-2 delivery that is
more biologically effective. In either case, the results are
thought provoking and support further studies of retrograde
infusion.
Retrograde coronary venous perfusion via coronary sinus
cannulation has been an established method for the infusion
of cardioplegic solution in cardiac surgery for many years.
The use of this route for the delivery of therapeutic agents
has also been previously reported, including retrograde
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infusion of nonrecombinant tissue-type plasminogen acti-
vator for coronary thrombolysis and delivery of L-arginine
to reduce infarct size (21,22). Recently, RCVP was shown
to be effective in the delivery of plasmid deoxyribonucleic
acid (DNA) to the heart (23). The reason RCVP appears to
yield more efficient myocardial delivery of proteins and
plasmid DNA than anterograde infusion is theorized to be
due to the lack of a so-called “resistance” vessel segment
between the infusion catheter and the capillary–venule
segment through which egress of the therapeutic agent is
thought to take place. Thus, RCVP at mildly elevated
perfusion pressures results in increased transvascular pres-
sure in the capillary-venule segments and promotes passage
of molecules across or through the endothelium. This is
shown diagrammatically in Figure 1.
Whether or not RCVP will be applicable to clinical
angiogenic therapy is presently unclear. Protein technology
is evolving and it is possible that the combination of
sustained-release protein preparations and RCVP will in-
crease the therapeutic efficacy of angiogenic protein delivery,
especially with newer protein agents, such as PR39, that
appear to have greater angiogenic potential (24). The
potential to use RCVP for gene delivery is also intriguing.
Currently, direct intramyocardial injection of plasmid DNA
or viral vectors encoding angiogenic factors is the most
widely used method to deliver angiogenic genes (7,8). To
establish RCVP as the preferred route for angiogenic gene
delivery, superior ease of use or greater efficacy relative to
either direct intramyocardial injection or anterograde IC
infusion must first be demonstrated. Other considerations
include the ability of RCVP to deliver agents to the right
coronary territory, the variability of coronary venous drain-
age among patients, and the consistent safety of the proce-
dure. Coronary sinus rupture is a known complication of
coronary sinus retroperfusion (25). However, RCVP does
appear to have the potential to be a clinically relevant route
to deliver molecular therapeutics to the heart.
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Figure 1. Retrograde coronary venous perfusion at increased pressure
augments egress of macromolecules from coronary venules and capillaries.
To accomplish retrograde coronary venous perfusion, the coronary sinus or
a large cardiac vein is cannulated, balloon occluded, and perfused retro-
grade at a pressure slightly higher than systolic venous occlusion pressure
(P). Because the only resistance to this increased pressure is on the arterial
side of the capillary-venule segments (R), the pressure within the capillaries
and venules increases. This increased pressure facilitates translocation of
macromolecules (e.g., fibroblast growth factor [FGF]-2) across the endo-
thelium and into the myocardium.
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